Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederir.nektar.com
Nektar Therapeutics News Releases
Get the latest updates from Nektar Therapeutics News Releases directly as they happen.
Follow now 74 followers
Latest posts
Last updated about 12 hours ago
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
about 13 hours ago
SAN FRANCISCO, Jan. 30, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today...
REZOLVE-AA Phase 2b Study of Rezpegaldesleukin Establishes Proof-of-Concept in Patients with Severe-to-Very-Severe Alopecia Areata
about 2 months ago
Achieved target product profile on the primary endpoint, with a mean percent...
Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025
about 2 months ago
SAN FRANCISCO , Dec. 15, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR)...
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
about 2 months ago
SAN FRANCISCO , Dec. 5, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR)...
New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting
3 months ago
Statistically significant and clinically meaningful improvements in mean ACQ-5 scores were reported...
Nektar Therapeutics Reports Third Quarter 2025 Financial Results
3 months ago
SAN FRANCISCO , Nov. 6, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR)...
Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
3 months ago
SAN FRANCISCO , Oct. 30, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR)...
Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets
3 months ago
SAN FRANCISCO , Oct. 28, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR)...
Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting
3 months ago
SAN FRANCISCO , Oct. 22, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR)...
Nektar Presents New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late-Breaker Oral Presentation at EADV 2025
4 months ago
Study met primary and key secondary endpoints at week 16 in patients...
Nektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025
5 months ago
SAN FRANCISCO , Sept. 9, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR)...
Nektar Therapeutics to Participate in Two Investor Conferences in September
5 months ago
SAN FRANCISCO , Sept. 3, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR)...